Ascendis Pharma AS (ASND) Actualités

Form S-8 - Securities to be offered to employees in employee benefit plans

Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference

COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs

– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000...

Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results

– Strong early U.S. YORVIPATH® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025

COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

- Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE...